A NSW Government website


Tissue Pathology and Diagnostic Oncology Research

Tissue Pathology and Diagnostic Oncology at RPA has a broad-based research program encompassing basic, translational and clinical studies in a wide range of organs, including skin, head and neck, lung, breast, colorectum, prostate, liver and pancreas. 

The melanoma group studies causes, diagnosis, prognostication and treatment in one of Australia's most common malignancies and are recognised international leaders in this field. The head and neck, lung, prostate and breast groups have established national and international profiles in pathology research focusing on diagnosis and prediction of behaviour in these tumours, as well as developing predictive markers for targeted therapy. 

Man wearing a white lab coat using a computer
SydneyConnect Image: Researcher Professor Richard Scolyer AO

Selected Grants

Amount awarded Grant and project details
$7,000,000 Medical Research Future Fund (MRFF), 2021-2026
Cartilage based stem cell therapies for joint deformity and facial disfigurement. A framework for point of care manufacturing and delivery (ARISTOCRAT). 
Investigators: Chung P, Clark J, Mukherjee P, Gupta R
$3,937,110 NHMRC Investigator Grant, 2023-2027
Melanoma: Getting the Diagnosis and Treatment Right for Better Patient Outcomes. 
Investigator: Scolyer R (CIA)
$3,750,000  CINSW, 2021-2025
Improving Outcomes in Head and Neck Cancer
Investigators: Clark JR, Gupta R, Ashford BA, Ranson M, Boyer MB, Lee J, Rizos H
$3,747,602 Cancer Council NSW Translational Program Grant, 2020-2024
INOVATe 2.0 - Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care - Phase 2: Evaluation, Implementation and Integration into Clinical Practice
Investigators: deFazio A, Harnett P, Friedlander M, Balleine R, Bowtell D, Samimi G, Brand A, Marsh D, Beale P, Anderson L
$3,230,670 Medical Research Future Fund (MRFF) -  International Clinical Trial Collaborations Grant Program RC Ideas Grant, 2020-2025
Circulating tumour DNA guidEd Therapy for stage IIB/C BRAF mutant positive mElanoma after surgiCal resecTION (DETECTION)
Investigators: Sandhu S, Dawson S-J, Long GV, Carlino M, Menzies A, Scolyer RA, Rizos H, Lorigan P, Atkinson V, Henderson M. 
$3,217,920 NHMRC Clinical Trials and Cohort Studies Grant, 2021-2026
Reconceiving early detection of melanoma
Investigators: Mar V, Janda M, Soyer P, Penas PF, Cust A, Morton R, Wolfe R, Scolyer R, Ge Z, Lawn C. 
$2,500,000 NHMRC Centres of Research Excellence, 2021-2025
Centre of Excellence in Skin Imaging and Precision Diagnosis
Investigators: Janda M, Soyer HP, Mar V, Fernandez-Penas P, Morton R, Cust A, Wolfe R, Scolyer RA, Caffery L, Ge Z.
$2,023,376 Medical Research Future Fund (MRFF) - Efficient Use of Existing Medicines Grant,2021-2025
NADINA Phase 3 trial comparing response driven neo-adjuvant combination of ipilimumab + nivolumab versus adjuvant nivolumab
Investigators: Long G, Scolyer RA, McArthur G, Menzies A, Spillane A, Carlino M, Gyorki D, Saw R, Lo S, Morton RL.
US$1,000,000 American Cancer Society (ACS) & Melanoma Research Alliance (MRA) Joint Award, 2020-2023
Molecular predictors and vulnerabilities of melanoma brain metastasis
Investigators: Davies M, Huse JT,  Gershenwald JE, Tetzlaff MT, Scolyer R
$859,000 NHMRC, 2021-2024
From Functional Genomics to Precision Medicine: Identifying the Cause and Finding Optimal Therapy
Investigators: Gupta R (CIB)
$598,000 NHMRC, 2020-2023
High Risk Cutaneous Squamous Cell Carcinoma: Defining Prognostic Markers of Metastases
Investigators: Gupta R (CIC)
$520,413 Medical Research Future Fund (MRFF),  2020-2023
Combination of Avelumab with Peptide Receptor Radionuclide Therapy (PRRT) or Conventional Fractionated Radiotherapy (RT) in Metastatic Merkel Cell Carcinoma (MCC). 
Investigators: Shackleton M, Poulsen M, Scolyer RA 
$148,150 Tour de Cure Community Grant 2022, 2022-2023
Digital Histological Imaging for Melanoma.
Investigator: Scolyer RA 
$100,000 NSW Government - Biospecimen Collection Grants, 2020-2024
Head and Neck Cancer Biobank.
Investigator: Gupta R (CIA)
$100,000 NSW Government - Biospecimen Collection Grants, 2020-2024
The Melanoma Institute Australia Biospecimen Bank – External Collections
Investigators: Scolyer RA

Our Publications


Ahmadi N, Kelly G, Low TH, Clark J, Gupta R. Molecular factors governing perineural invasion in malignancy. Surg Oncol. 2022 Apr 14;42:101770. doi: 10.1016/j.suronc.2022.101770. Epub ahead of print. PMID: 35490532.
Attrill GH, Lee H, Tasker AT, Adegoke NA, Ferguson AL, da Silva IP, Saw RPM, Thompson JF, Palendira U, Long GV, Ferguson PM, Scolyer RA, Wilmott JS. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome. Front Immunol. 2022 Aug 8;13:979993. doi: 10.3389/fimmu.2022.979993. eCollection 2022. PMID: 36003398
Attrill GH, Owen CN, Ahmed T, Vergara IA, Colebatch AJ, Conway JW, Nahar KJ, Thompson JF, Pires da Silva I, Carlino MS, Menzies AM, Lo S, Palendira U, Scolyer RA^, Long GV^, Wilmott JS^ (^ These authors contributed equally to this manuscript). Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. J Immunother Cancer. 2022 Jun;10(6):e004771. doi: 10.1136/jitc-2022-004771. PMID: 35688560
Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL. Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. EBioMedicine. 2022 Aug;82:104143. doi: 10.1016/j.ebiom.2022.104143. Epub 2022 Jul 7. PMID: 35810563
Barnhill R, van Laere S, Vermeulen P, Roman-Roman S, Gardrat S, Alsafadi S, Tarin M, Champenois G, Nicolas A, Matet A, Cassoux N, Servois V, Rodrigues M, Scolyer R, Lazar A, Romano E, Piperno-Neumann S, Mariani P, Lugassy C.  L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases. Lab Invest. 2022 Nov;102(11):1214-1224. doi: 10.1038/s41374-022-00803-w. Epub 2022 Jun 7. PMID: 35672380 & 36775447
Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. J Transl Med. 2022 Jun 15;20(1):271. doi: 10.1186/s12967-022-03472-x. PMID: 35706041
Busam KJ, Judge MJ, Bichakjian CK, Coit D, Kutzner H, Requena L, Scolyer RA, Stefanato CM, Wood BA, Walsh NM. Dataset for the Reporting of Merkel Cell Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Am J Surg Pathol. 2022 Nov 1;46(11):1583-1591. doi: 10.1097/PAS.0000000000001959. Epub 2022 Aug 25. PMID: 36001458
Chetwood JD, Shin JS, Koorey D. Gastrointestinal: Esophageal nodularity in a 32-year-old female patient. Journal of Gastroenterology and Hepatology. First published: 20 March 2022 https://doi.org/10.1111/jgh.15807
Cheung VKY, Hulme K, Schifter M, Palme C, Low TH, Clark J, Gupta R. Oral Epithelial Dysplasia: A Review of Diagnostic Criteria for Anatomic Pathologists. Adv Anat Pathol. 2022 Jul 1;29(4):227-240.
Cho D, Lord  S, Simes J, Cooper WA, Friedlander M, Bae S, Lee CK. Next Generation Sequencing, Should I Use anti-HER2 Therapy for HER2 Amplified Tumors Off-Label? Illustrating an Extrapolation Framework. Therapeutic Advances in Medical Oncology. 2022; 14: 17588359221112822.
Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, Grainge C, Maher TM, Navaratnam V, Hubbard R, Hopkins PMA, Reynolds PN, Chapman S, Zappala C, Keir GJ, Cooper WA, Mahar AM, Ellis S, Goh, N, De Jong E, Cha L, Tan DBA, Leigh L, Oldmeadow C, Walters EH, Jenkins RG, Moodley Y. Biomarker Signatures for Progressive Idiopathic Pulmonary Fibrosis. European Respiratory Journal 2022; 59: 2101181.
Cochran AJ, Wen DR, Huang RR, Abrishami P, Smart C, Binder S, Scolyer RA, Thompson JF, Stern S, Van Kreuningen L, Elashoff DE, Sim MS, Wang HJ, Faries MB; MSLT-I Study Group. Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Eur J Surg Oncol. 2022 Jun;48(6):1280-1287. doi: 10.1016/j.ejso.2022.01.021. Epub 2022 Feb 12. PMID: 35246348
Colebatch AJ*, Paver EC*, Vergara IA, Thompson JF, Long GV, Wilmott JS, Scolyer RA (*authors contributed equally to the work and are considered co-first authors). Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Pathology. 2022 Aug;54(5):533-540. doi: 10.1016/j.pathol.2021.12.289. Epub 2022 Mar 2. PMID: 35248370
Colebatch AJ, Adhikari C, Diefenbach RJ, Rawson RV, Ferguson PM, Rizos H, Long GV, McCarthy SW, Thompson JF, Wilmott JS, Scolyer RA. Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevi. Am J Surg Pathol. 2022 Aug 1;46(8):1048-1059. doi: 10.1097/PAS.0000000000001902. Epub 2022 Apr 20. PMID: 35439782
Conway JW, Braden J, Wilmott JS, Scolyer RA†, Long GV†, Pires da Silva I†. (†These authors contributed equally to this work and share senior authorship). The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Front Immunol. 2022 Nov 17;13:1030147. doi: 10.3389/fimmu.2022.1030147. eCollection 2022. PMID: 36466910 
Conway JW, Rawson RV, Lo S, Ahmed T, Vergara IA, Gide TN, Attrill GH, Carlino MS, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Shivalingam B, Menzies AM, Wilmott JS, Long GV^, Scolyer RA^, Pires da Silva I^ (^these authors contributed equally to this manuscript). Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. J Immunother Cancer. 2022 Sep;10(9):e004884. doi: 10.1136/jitc-2022-004884. PMID: 36096531
Dennis C, Prince D, Moayed-Alaei L, Remash D, Bowen D, Strasser S, Crawford M, Pulitano C, Kench J, McCaughan GW, McKenzie C, Liu K. Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation. In press, Frontiers in Oncology, 2022.
Dhanji P, Chetwood JD, Shin JS, Tamilarasan AG. Metastatic Crohn's disease: treat-to-target approach and review of the literature. Journal of Gastroenterology and Hepatology 2022 Sep 1. Vol. 37:138-139.
Diefenbach RJ, Lee JH, Stewart A, Menzies AM, Carlino MS, Saw RPM, Stretch JR, Long GV, Scolyer RA, Rizos H. Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Front Oncol. 2022 Apr 12;12:820510. doi: 10.3389/fonc.2022.820510. eCollection 2022. PMID: 35494035
El Sharouni MA, Rawson RV, Sigurdsson V, Witkamp AJ, van Gils CH, Scolyer RA, Thompson JF*, van Diest PJ*, Lo SN*. (*Contributed equally). The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultra-thick melanomas (≥15mm in thickness). J Am Acad Dermatol. 2022 Aug;87(2):298-305. doi: 10.1016/j.jaad.2022.01.040. Epub 2022 Feb 1. PMID: 35121073
El Sharouni MA, Scolyer RA, van Gils CH, Ch'ng S, Nieweg OE, Pennington TE, Saw RP, Shannon K, Spillane A, Stretch J, Witkamp AJ, Sigurdsson V, Thompson JF, van Diest PJ*, Lo SN*. (*contributed equally). Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. Eur J Cancer. 2022 May;167:133-141. doi: 10.1016/j.ejca.2021.12.036. Epub 2022 Feb 22. PMID: 335216870
Ferguson A, Sharman A, Allen R, Ye T, Lee JH, Low TH, Ch'ng S, Palme CE, Ashford B, Ranson M, Clark JR, Patrick E, Gupta R*, and Palendira U*. High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma. Clin Cancer Res. 2022 Nov 1;28(21):4677-4688.
Fielder T, Butler J, Tierney G, Holmes M, Lam B, Satgunaseelan L, Colebatch A, Mahar A, Gupta R, O'Toole S, Cooper WA. ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1. Pathology. 2022; 54:399-403.
Fielder T, Watts F, Howden C, Gupta R, McKenzie C. Why Choose a Pathology Career? Arch Pathol Lab Med. 2022 Jul 1;146(7):903-910. doi: 10.5858/arpa.2021-0118-OA. PMID: 34637490.
Folmsbee J, Zhang L, Lu X, Rahman J, Gentry J, Conn B, Vered M, Roy P, Gupta R, Lin D, Samankan S, Dhorajiva P, Peter A, Wang M, Israel A, Brandwein-Weber M, Doyle S. Histology segmentation using active learning on regions of interest in oral cavity squamous cell carcinoma. J Pathol Inform. 2022 Sep 27;13:100146.
Gaetano L, Domenico B, Lo SN, Hamed T, Potter AJ, Thompson JF, Scolyer RA, Guitera P. Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas. JAAD Int. 2022 Jun 16;8:102-108. doi: 10.1016/j.jdin.2022.06.001. eCollection 2022 Sep. PMID: 35875393
Ghosh YA, Gupta R, Al Maruf DA, Cheng K, Mukherjee P, Clark JR. "Surgical technique: A novel pedicled periosteal scapular flap to facilitate bone growth in an Ovine model". J Plast Reconstr Aesthet Surg. 2022 Apr;75(4):1497-1520. doi: 10.1016/j.bjps.2022.01.048. Epub 2022 Jan 31. PMID: 35140043.
Gu B, Liu K, McKenzie C, MacGregor D, Corte C. Gastrointestinal: Autoimmune enteropathy associated with thymoma. J Gastroenterol Hepatol. 2022 Apr;37(4):606. doi: 10.1111/jgh.15692. Epub 2021 Oct 10. PMID: 34632628.
Guitera P, Waddell A, Paton E, Fogarty GB, Hong A, Scolyer RA, Stretch JR, O'Donnell BA, Pellacani G. Re: Reply to letter to the editor re: 'A practical guide on the use of Imiquimod cream to treat Lentigo Maligna' (original PMID: 34529272). Australas J Dermatol. 2022 May;63(2):e198-e199. doi: 10.1111/ajd.13797. Epub 2022 Feb 2 PMID: 35107826.
Hanna S, Marinos E, Bryan D, Ahmed T, Lo SN, Carlino MS, Smith A, Cairns G, Shannon K, Long GV, Scolyer RA, Saw RPM. Effect of the SunSafe Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. Clin Exp Dermatol. 2022 Nov;47(11):1956-1967. doi: 10.1111/ced.15220. Epub 2022 Aug 24. PMID: 35434843
Heyneman S, Prosser N, Lee J, Mahar A, Anderson L, Kao SC, Cooper WA. Squamous Cell Carcinoma Differentiation at Progression as a Resistance Mechanism in Metastatic Non-Small Cell Lung carcinoma Harbouring a Targetable Mutation. Pathology 2022;54:935-938.
Ho G, Schwartz RJ, Regio Pereira A, Dimitrou F, Paver E, McKenzie C, Saw RPM, Scolyer RA, Long GV, Guitera P. Reflectance confocal microscopy - a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e583-e585. doi: 10.1111/jdv.18076. Epub 2022 Mar 29. PMID: 35285090.
Hulme KR, Mahar A, Campbell RG, Clifton-Bligh R, Gill AJ, Palme CE, Gupta R. Phosphaturic Mesenchymal Tumors in the Head and Neck Demonstrate a Broad Clinical and Morphologic Spectrum. Head Neck Pathol. 2022 Feb 4. doi: 10.1007/s12105-022-01419-8. Epub ahead of print. PMID: 35119617.
Hurrell MJL, Heller GZ, Elliott MS, Gao K, Ebrahimi A, Clark JR, Shannon K, Palme CE, Wykes J, Gupta R, Ch'ng S, Nguyen KM, Low TH. Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma. Ann Surg Oncol. 2022 May 15. doi: 10.1245/s10434-022-11863-z. Epub ahead of print. PMID: 35569073.
Jain D, Nambirajan A, Chen G, Geisinger K et al for the IASLC Pathology Committee. NSCLC subtyping in conventional cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group survey to determine specific cytomorphological criteria for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol. 2022; 17;6:793-805.
Jobson D, Roffey B, Arnold C, Azzi A, Button-Sloan A, Dawson T, Fernandez-Penas P, Fishburn P, Gyorki DE, Hiscutt EL, Jakrot V, Lilleyman A, Lochhead A, Long GV, Mailer S, Mann G, McCormack CJ, Muir J, Pratt GF, Scolyer RA, Shackelton M, Shumack S, Soyer HP, Tan CG, Webb A, Zalcberg J, Morton R, Mar V. Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study. Australas J Dermatol. 2022 Aug;63(3):344-351. doi: 10.1111/ajd.13848. Epub 2022 Apr 29. PMID: 35486539
Kynaston A, Liu K, Davis A, Kao S, McKenzie C. A case of steroid responsive nivolumab induced cholangitis. Pathology. 2022 Feb 10:S0031-3025(22)00031-9. doi: 10.1016/j.pathol.2021.11.009. Epub ahead of print. PMID: 35153072.
Lawless AK*, Coker DJ*, Lo SN, Ahmed T, Scolyer RA, Ch'ng S, Nieweg OE, Shannon K, Spillane A, Stretch JR, Thompson JF#, Saw RPM# (*These authors contributed equally to the work and are considered co-first authors. #These authors contributed equally to the work and are considered co-senior authors.) Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases. Ann Surg Oncol. 2022 Oct;29(11):7019-7028. doi: 10.1245/s10434-022-11997-0. Epub 2022 Jun 30. PMID: 35771368
Li AT, Miin Yip J, Choksi H, London K, Potter AJ, Lo SN, Saw RPM, Shannon KF, Pires da Silva I, Varey AHR, Menzies AM, Long GV, Shivalingam B, Scolyer RA, Thompson JF, Ch'ng S. Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. Melanoma Res. 2022 Aug 1;32(4):260-268. doi: 10.1097/CMR.0000000000000827. Epub 2022 May 13. PMID: 35579680
Lô SN, Ma J, Manuguerra M, Moreno-Betancur M, Scolyer RA, Thompson JF. Competing risks analysis with missing cause-of-failure-penalized likelihood estimation of cause-specific Cox models. Stat Methods Med Res. 2022 May;31(5):978-994. doi: 10.1177/09622802211070254. Epub 2022 Jan 17.  PMID: 35037794
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators.* (*A complete list of investigators who participated in the KEYNOTE-716 study is provided in Table 1 of the Supplementary Appendix, available at NEJM.org). Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. PMID: 35367007
Luo L, Shen R, Arora A, Orlow I, Busam KJ, Lezcano C, Lee TK, Hernando E, Gorlov I, Amos C, Ernstoff MS, Seshan V, Cust AE, Wilmott J, Scolyer RA, Mann G, Nagore E, Funchain P, Ko J, Ngo P, Edmiston SN, Conway K, Googe PB, Ollila D, Lee JE, Fang S, Rees JR, Thompson CL, Gerstenblith M, Bosenberg M, Gould Rothberg B, Osman I, Saenger Y, Reynolds AZ, Schwartz M, Boyce T, Holmen S, Brunsgaard E, Bogner P, Kuan PF, Wiggins C, Thomas NE, Begg CB, Berwick M; For InterMEL. Landscape of Mutations in Early Stage Primary Cutaneous Melanoma - An InterMEL Study. Pigment Cell Melanoma Res. 2022 Nov;35(6):605-612. doi: 10.1111/pcmr.13058. Epub 2022 Aug 12. PMID: 35876628
Marsland M, Dowdell A, Jiang CC, Wilmott JS, Scolyer RA, Zhang XD, Hondermarck H#, Faulkner S.# (#contributed equally to the study). Expression of NGF/proNGF and Their Receptors TrkA, p75NTR and Sortilin in Melanoma. Int J Mol Sci. 2022 Apr 12;23(8):4260. doi: 10.3390/ijms23084260.. PMID: 35457078
McLean AEB, Kao SC, Barnes DJ, Wong KKH, Scolyer RA, Cooper WA*, Kohonen-Corish MRJ*. (*These authors contributed equally). The Emerging Role of the Lung Microbiome and its importance in Lung Cancer Diagnosis and Treatment. Lung Cancer. 2022 Jan 20;165:124-132. doi: 10.1016/j.lungcan.2022.01.011. Online ahead of print. PMID: 35123155 and PMID: 35279297 (Corrigendum)
Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch F, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, Yu H, Sholl LM, Brambilla E, Chou TY, Connolly C, Wistuba I, Kerr KM, Lantuejoul S, IASLC Pathology Committee. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee. Journal of Thoracic Oncology. 2022; 17:1335-1354 https://doi.org/10.1016/j.jtho.2022.09.109
Moncrieff MD, Lo SN, Scolyer RA, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyova R, Mason J, Wilson ED, Nolan G, Jones RP, Sondak VK, Thompson JF, Zager JS. ASO Visual Abstract: Evaluation of Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International Multicenter Study. Ann Surg Oncol. 2022 May 25. doi: 10.1245/s10434-022-11822-8. Online ahead of print. PMID: 35612683
Moncrieff MD, Lo SN, Scolyer RA, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyova R, Mason J, Wilson ED, Nolan G, Pritchard Jones R, Johansson I, Olofsson Bagge R, Wright LJ, Patel NG, Sondak VK*, Thompson JF*, Zager JS* (*Joint senior authors with equal merit (alphabetical)). Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. J Clin Oncol. 2022 Dec 1;40(34):3940-3951. doi: 10.1200/JCO.21.02488. Epub 2022 Jul 18. PMID: 35849790
Muir CA, Wood CCG, Clifton-Bligh RJ, Long GV, Scolyer RA, Carlino MS, Menzies AM*, Tsang VHM* (*contributed equally and are co-senior authors of this research article). Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events. J Clin Endocrinol Metab. 2022 Apr 19;107(5):e1843-e1849. doi: 10.1210/clinem/dgac059. PMID: 35104870 (nb: 14.5.2: this paper was one of the top 10 percent of articles published in the journal in 2020-2021, assessed by rate of citation)
Multicenter Selective Lymphadenectomy Trials Study Group, Crystal JS, Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Neves R, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, Hsueh EC, MacKenzie-Ross A, Kelley M, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Ariyan CE, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, McMasters KM, O'Donoghue C, van der Westhuizen A, Sardi A, Barth R, Barone R, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Molina M, Testori AAE, Foshag LJ, Van Kreuningen L, Wang HJ, Sim MS, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA Surg. 2022 Sep 1;157(9):835-842. doi: 10.1001/jamasurg.2022.2055. PMID: 35921122
Nahar KJ*, Marsh-Wakefield F*, Rawson RV, Gide TN, Ferguson AL, Allen RO, Quek C, Pires da Silva I, Tattersall S, Kiely CJ, Sandanayake N, Carlino MS, McCaughan G, Wilmott JS, Scolyer RA, Long GV, Menzies AM*, Palendira U* (* Equal contributions). Distinct pre-treatment innate immune landscape and post-treatment T cell responses underlie the development of combination therapy-induced colitis. JCI Insight. 2022 Nov 8;7(21):e157839. doi: 10.1172/jci.insight.157839. PMID: 36173679
Newell F#, Pires da Silva I#, Johansson PA#, Menzies AM#, Wilmott JS#, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK§, Scolyer RA§, Waddell N§, Long GV§. (#These authors contributed equally to this work. §These authors jointly supervised this work). Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell. 2022 Jan 10;40(1):88-102.e7. doi: 10.1016/j.ccell.2021.11.012. Epub 2021 Dec 23. PMID: 34951955
Newell F*, Johansson PA*, Wilmott JS, Nones K, Lakis V, Pritchard AL, Lo SN, Rawson RV, Kazakoff SH, Colebatch AJ, Koufariotis LT, Ferguson PM, Wood S, Leonard C, Law MH, Brooks KM, Broit N, Palmer JM, Couts KL, Vergara IA, Long GV, Barbour AP, Nieweg OE, Shivalingam B, Robinson WA, Stretch JR, Spillane AJ, Saw RPM, Shannon KF, Thompson JF, Mann GJ, Pearson JV, Scolyer RA#, Waddell N#, Hayward NK# (# These authors jointly supervised this work * These authors contributed equally). Comparative genomics provides etiological and biological insight into the melanoma subtypes. Cancer Discov. 2022 Dec 2;12(12):2856-2879. doi: 10.1158/2159-8290.CD-22-0603. PMID: 36098958
Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr K, Lantuejoul S, Noguchi M, Papotti M, Rekhtman N, Scagliotti G, van Schil P, Sholl L, Yatabe Y, Yoshida A, Travis WD. The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. Journal of Thoracic Oncology. 2022; 17:362-387.
Park JS, Ben-David M, McKenzie C, Sandroussi C. Cytomegalovirus adrenalitis mimicking adrenal metastasis in an immunocompetent patient. J Surg Case Rep. 2022 Mar 26;2022(3):rjac122. doi: 10.1093/jscr/rjac122. PMID: 35355581; PMCID: PMC8963155.
Parker A, Bowman E, Zingone A, Ryan BM, Cooper WA, Kohonen-Corish M, Harris CC, Cox TR. Extracellular matrix Profiles determine risk and prognosis of the Squamous Cell Carcinoma Subtype of Non-Small Cell Lung Carcinoma Extracellular matrix profiles determine squamous non-small cell lung cancer risk and prognosis. 2022. Genome Medicine. 2022; 14: 1-29.
Paver E, Aivazian K, Maclean F, Long GV, Spillane AJ, Wilmott JS, Scolyer RA. Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma. Pathology. 2022 Oct 29:S0031-3025(22)00277-X. doi: 10.1016/j.pathol.2022.08.011. Online ahead of print. PMID: 36400594
Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, Shin JS, O'Toole S, Anderson L, Scolyer RA, Gupta R. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021 Feb;53(2):141-156
Pennington TE, Zhao CY, Colebatch AJ, Fernandez-Peñas P, Guitera P, Burke H, Scolyer RA, Menzies AM, Carlino MS, Lo S, Long GV, Saw RP. Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. Australas J Dermatol. 2022 May;63(2):e133-e137. doi: 10.1111/ajd.13807. Epub 2022 Feb 21. PMID: 35188271
Pereira AR*, Corral-Forteza M*, Collgros H, El Sharouni MA, Ferguson PM, Scolyer RA, Guitera P (*contributed equally). Dermoscopic features and screening strategies for the detection of small-diameter melanomas. Clin Exp Dermatol. 2022 May;47(5):932-941. doi: 10.1111/ced.15094. Epub 2022 Feb 15. PMID: 34997617
Pires da Silva I#, Ahmed T#, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P, Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV§, Lo SN§, Menzies AM§ (# §These authors contributed equally). Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J Clin Oncol. 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701. Epub 2022 Feb 10. PMID: 35143285
Potter AJ, Colebatch AJ, Rawson RV, Ferguson PM, Cooper WA, Gupta R, O'Toole S, Saw RPM, Ch'ng S, Menzies AM, Long GV, Scolyer RA. Pathologist-initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology. 2022 Aug;54(5):526-532. doi: 10.1016/j.pathol.2021.12.290. Epub 2022 Mar 3. PMID: 35249747
Rawson RV, Shteinman ER, Ansar S, Vergara IA, Thompson JF, Long GV, Scolyer RA, Wilmott JS.  Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics. Pathology. 2022 Dec;54(7):863-873. doi: 10.1016/j.pathol.2022.05.012. Epub 2022 Jul 31. PMID: 35987723
Reijers IL, Menzies AM, Van Akkooi AC, Versluis JM, Van Den Heuvel NM, Saw RP, Pennington TE, Kapiteijn E, Van Der Veldt AA, Suijkerbuijk KP, Hospers GA, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature medicine. 2022 Jun;28(6):1178-88.
Reijers IL, Rawson RV, Colebatch AJ, Rozeman EA, Menzies AM, van Akkooi AC, Shannon KF, Wouters MW, Saw RP, van Houdt WJ, Zuur CL. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma. JAMA surgery. 2022 Apr 1;157(4):335-42.
Risbey C, Fielder T, Steffens D, Shin J-S, Solomon M. Patterns of DNA mismatch repair protein expression for primary and recurrent colorectal cancer at an advanced surgical unit: a retrospective audit. Colorectal Disease 2022; DOI: 10.1111/codi.16391
Satgunaseelan L, Porazinski S, Strbenac D, Istadi A, Willet C, Chew T, Sadsad R, Palme CE, Lee JH, Boyer M, Yang JYH, Clark JR, Pajic M, Gupta R. Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy. Front Oncol. 2021 Nov 29;11:750852.
Satgunaseelan L, Strbenac D, Cali Willet C, Chew T, Sadsad R, Wykes J, Low H, Cooper WA, Lee CS, Palme CE, Yang J, Clark JR Gupta R. Whole Genome Duplication in Oral Squamous Cell Carcinoma in Patients Younger Than 50 years: Implications for Prognosis and Adverse Clinicopathological Factors. Genes, Chromosomes and Cancer. 2022;61:561-571.
Satgunaseelan L, Strbenac D, Tadi S, Nguyen K, Wykes J, Palme CE, Low TH, Yang JYH, Clark JR, Gupta R. Viral Integration Plays a Minor Role in the Development and Prognostication of Oral Squamous Cell Carcinoma. Cancers (Basel). 2022 Oct 24;14(21):5213.
Satgunaseelan L, Strbenac D, Willet C, Chew T, Sadsad R, Wykes J, Low HTH, Cooper WA, Lee CS, Palme CE, Yang JYH, Clark JR, Gupta R. Whole Genome Duplication in Oral Squamous Cell Carcinoma in Patients Younger Than 50 years: Implications for Prognosis and Adverse Clinicopathological Factors. Genes Chromosomes Cancer. 2022 Sep;61(9):561-571.
Schwartz RJ, Ho G, Smith A, Collgros H, Regio Pereira A, Gouveia B, Long GV, Menzies AM, Potter AJ, Paver E, Star P, Scolyer RA, Martin LK.. Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy. J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e445-e448. doi: 10.1111/jdv.17940. Epub 2022 Jan 28. PMID: 35043483
Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O'Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, Long GV. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: Practical guidance for the Australian setting. Pathology. 2022 Feb;54(1):6-19. doi: 10.1016/j.pathol.2021.11.002. Epub 2021 Dec 20. PMID: 34937664
Scolyer RA. Pathology: The Next Chapter. Editorial. Pathology. 2022 Feb;54(1):4-5. doi: 10.1016/j.pathol.2021.12.001. Epub 2022 Jan 10. PMID: 35022138
Semsarian CR, Ma T, Nickel B, Scolyer RA, Ferguson PM, Soyer HP, Parker L, Barratt A, Thompson JF, Bell KJL. Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? Br J Dermatol. 2022 Jan 10. doi: 10.1111/bjd.21010. Online ahead of print. PMID: 35007335
Semsarian CR, Ma T, Nickel B, Scolyer RA, Ferguson PM, Soyer HP, Parker L, Barratt A, Thompson JF, Bell KJL. Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? Br J Dermatol. 2022 Jun;186(6):1030-1032. doi: 10.1111/bjd.21010. Epub 2022 Apr 7. PMID: 35007335
Seviiri M, Scolyer RA, Bishop DT, Newton-Bishop JA, Iles MM, Lo SN, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Gordon SD, Olsen CM, Whiteman DC, Landi MT, Thompson JF, Long GV, MacGregor S, Law MH. Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting. J Transl Med. 2022 Sep 5;20(1):403. doi: 10.1186/s12967-022-03613-2. PMID: 36064556
Shklovskaya E, Pedersen B, Stewart A, Simpson JOG, Ming Z, Irvine M, Scolyer RA, Long GV, Rizos H. Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers.. Cancers (Basel). 2022 Oct 3;14(19):4830. doi: 10.3390/cancers14194830. PMID: 36230753
Shteinman ER, Wilmott JS, da Silva IP, Long GV*, Scolyer RA*, Vergara IA.* (*These authors contributed equally to this work). Causes, consequences and clinical significance of aneuploidy across melanoma subtypes. Front Oncol. 2022 Oct 6;12:988691. doi: 10.3389/fonc.2022.988691. eCollection 2022. PMID: 36276131
Simpson RC*, Shanahan ER*, Batten M*, Reijers ILM*, Read M#, Silva IP#, Versluis JM#, Ribeiro R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV (*#these authors have contributed equally). Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and gut microbiome. Nat Med. 2022 Nov;28(11):2344-2352. doi: 10.1038/s41591-022-01965-2. Epub 2022 Sep 22. PMID: 36138151
Smith AL, Watts CG, Henderson M, Long GV, Rapport F, Saw RPM, Scolyer RA, Spillane AJ, Thompson JF, Cust AE. Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework. Implement Sci Commun. 2022 Oct 1;3(1):103. doi: 10.1186/s43058-022-00351-w.  PMID: 36183121
Star P, Jackett LA, Cheung K, Wilmott JS, Ho G, Smith A, Long GV, Scolyer RA, Martin LK. Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: pathogenesis, immunohistochemical analysis and treatment. Dermatol Ther. 2022 Jun;35(6):e15472. doi: 10.1111/dth.15472. Epub 2022 Apr 5. PMID: 35347815
Thomson A, Denis M, Totaro R, Cooper W, Dennis M. Fulminant Delta COVID-19 myocarditis: a fatal case of primary cardiac dysfunction. Eur Heart J Case Rep. 2022 Apr 13;6(4):ytac142. doi: 10.1093/ehjcr/ytac142
van Akkooi ACJ*, Hieken TJ*, Burton EM*, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ#, Ross MI#, International Neoadjuvant Melanoma Consortium (INMC) (*shared first authorship, #Shared Senior Authorship). Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Jun;29(6):3694-3708. doi: 10.1245/s10434-021-11236-y. Epub 2022 Jan 28. PMID: 35089452 & 35426590 (correction).
Varey AHR, Williams GJ, Lo SN, Taing CY, Maurichi A, Santinami M, Scolyer RA, Thompson JF. Clinical Management of Melanocytic Tumours of Uncertain Malignant Potential (MelTUMPs), including Melanocytomas: A Systematic Review and Meta-Analysis. J Eur Acad Dermatol Venereol. 2022 Oct 17. doi: 10.1111/jdv.18665. Online ahead of print. PMID: 36251355
Walsh  SLF, Mackintosh, JA, Calandriello L, Silva M, Sverzellati N, Larici AR, Humphries SM, Lynch DA, Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Zappala C, Keir G, Cooper WA, Mahar AM, Ellis S, Wells AU, Corte TJ. Deep learning-based outcome prediction in progressive fibrotic lung disease using high-resolution computed tomography. American Journal of Respiratory and Critical Care Medicine. 2022 Jun 13.  doi: 10.1164/rccm.202112-2684OC. Online ahead of print
Wang KYX*, Pupo GM*, Tembe V*, Patrick E, Strbenac D, Schramm SJ, Thompson JF, Scolyer RA, Muller S, Tarr G, Mann GJ*, Yang JYH* (*equal contribution). Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine. NPJ Digit Med. 2022 Jul 4;5(1):85. doi: 10.1038/s41746-022-00618-5. PMID: 35788693
Wang M†, Zadeh S†, Pizzolla A, Thia K, Gyorki DE, McArthur GA, Scolyer RA, Long G, Wilmott JS, Andrews MC, Au-Yeung G, Weppler A, Sandhu S, Trapani JA, Davis MJ, Neeson PJ (†contributed equally). Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. J Immunother Cancer. 2022 Apr;10(4):e004095. doi: 10.1136/jitc-2021-004095. PMID: 35383113
Watts C; Spillane A; Henderson MA; Cust, A; Braithwaite J; Gyorki DE; Hong AM; Kelly JW; Long GV; Mar VJ; Menzies AM; Morton, RL; Rapport, F; Saw RPM; Schmid H; Scolyer RA; Smith, AL; Winder A; Mann, GJ. Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. Med J Aust 14 Mar 2022 doi: 10.5694/mja2.51424. PMID: TBC
Weiss JM, Hunter MV, Cruz NM, Baggiolini A, Tagore M, Ma Y, Misale S, Marasco M, Simon-Vermot T, Campbell NR, Newell F, Wilmott JS, Johansson PA, Thompson JF, Long GV, Pearson JV, Mann GJ, Scolyer RA, Waddell N, Montal ED, Huang TH, Jonsson P, Donoghue MTA, Harris CC, Taylor BS, Xu T, Chaligné R, Shliaha PV, Hendrickson R, Jungbluth AA, Lezcano C, Koche R, Studer L, Ariyan CE, Solit DB, Wolchok JD, Merghoub T, Rosen N, Hayward NK, White RM. Anatomic position determines oncogenic specificity in melanoma. Nature. 2022 Apr;604(7905):354-361. doi: 10.1038/s41586-022-04584-6. Epub 2022 Mar 30. PMID: 35355015
Wilson A, Goltsman D, Nankervis J, Clark J, Gupta R, Ashford B. Defining the incidence of cutaneous squamous cell carcinoma in coastal NSW Australia. Australas J Dermatol. 2022 May;63(2):213-216. doi: 10.1111/ajd.13830. Epub 2022 Apr 9. PMID: 35397123.
Woodford R, Zhou D, Lord SJ, Marschner I, Cooper WA, Lewis CR, John T, Yang JCH, Lee CK. PD-L1 expression as a prognostic biomarker for patients treated with chemotherapy for metastatic non-small cell lung cancer. Future Oncology. 2022; 18:14.
Yabe TE, King K, Russell S, Satgunaseelan L, Gupta R, Chen J, Ashford B. MYH9 mutation and squamous cell cancer of the tongue in a young adult: a novel case report. Diagn Pathol. 2022 Feb 6;17(1):23.
Yaseen Z, Gide TN, Conway JW, Potter AJ, Quek C, Hong AM, Long GV, Scolyer RA, Wilmott JS. Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-profiling Melanoma. Front Mol Biosci. 2022 May 19;9:810858. doi: 10.3389/fmolb.2022.810858. PMID: 35664673
Yu SL, Hsiao YJ, Cooper WA (equal 1st author),, Choi YL, Avilés-Salas A, Chou TY, Coudry R, Raskin GA, Fox SB, Huang CC, Jeon YK, Ko YH, Ku WH, Kwon GY, Leslie C, Lin MC, Lou PJ, Scapulatempo-Neto C, Mendoza Ramírez S, Savelov N, Shim HS, Lara Torres CO, Cunha IW, Zavalishina L, Chen YM. The Ring study: an international comparison of PD-L1 diagnostic assays and their interpretation in NSCLC, HNSCC and UC. Pathology. Available online 1 Oct 2022. https://doi.org/10.1016/j.pathol.2022.07.016
Yung AE, Crouch G, Varey AHR, Lo S, Elliott MS, Lee J, Rawson R, Gupta R, Hong AM, Clark JR, Ch'ng S. Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck. Ann Surg Oncol. 2022 Apr 13. doi: 10.1245/s10434-022-11669-z. Epub ahead of print. PMID: 35419758.